Judith S Renes1, Jaap van Doorn2, Anita C S Hokken-Koelega3,4. 1. Department of Paediatrics, Subdivision of Endocrinology, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands, j.renes@erasmusmc.nl. 2. Department of Genetics, Section of Metabolic Diagnostics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands. 3. Department of Paediatrics, Subdivision of Endocrinology, Erasmus University Medical Centre, Sophia Children's Hospital, Rotterdam, The Netherlands. 4. Dutch Growth Research Foundation, Rotterdam, The Netherlands.
Abstract
BACKGROUND: The reason for the insufficient catch-up growth seen in 10% of children born small for gestational age (SGA) is poorly understood. Disturbances in the growth hormone (GH) - insulin-like growth factor (IGF) axis might underlie this failure to show sufficient catch-up growth. CONCLUSION: This review summarizes insights gained in the molecular and (epi) genetic mechanisms of the GH-IGF axis in short children born SGA. The most notable anomalies of the IGF system are the lowered IGF-I levels in both cord blood and the placenta, and the increased expression of IGF-binding proteins (IGFBP)-1 and IGFBP-2, which inhibit IGF-I, in the placenta of SGA neonates. These observations suggest a decreased bioactivity of IGF-I in utero. IGF-I levels remain reduced in SGA children with short stature, as well as IGFBP-3 and acid-labile subunit levels. Proteolysis of IGFBP-3 appears to be increased.
BACKGROUND: The reason for the insufficient catch-up growth seen in 10% of children born small for gestational age (SGA) is poorly understood. Disturbances in the growth hormone (GH) - insulin-like growth factor (IGF) axis might underlie this failure to show sufficient catch-up growth. CONCLUSION: This review summarizes insights gained in the molecular and (epi) genetic mechanisms of the GH-IGF axis in short children born SGA. The most notable anomalies of the IGF system are the lowered IGF-I levels in both cord blood and the placenta, and the increased expression of IGF-binding proteins (IGFBP)-1 and IGFBP-2, which inhibit IGF-I, in the placenta of SGA neonates. These observations suggest a decreased bioactivity of IGF-I in utero. IGF-I levels remain reduced in SGA children with short stature, as well as IGFBP-3 and acid-labile subunit levels. Proteolysis of IGFBP-3 appears to be increased.
Authors: Anja Tzschoppe; Christina Riedel; Rüdiger von Kries; Ellen Struwe; Wolfgang Rascher; Helmuth G Dörr; Matthias W Beckmann; Ralf L Schild; Tamme W Goecke; Allan Flyvbjerg; Jan Frystyk; Jörg Dötsch Journal: Clin Endocrinol (Oxf) Date: 2015-07-23 Impact factor: 3.478
Authors: Horacio M Domené; Paula A Scaglia; Alicia S Martínez; Ana C Keselman; Liliana M Karabatas; Viviana R Pipman; Sonia V Bengolea; María C Guida; María G Ropelato; María G Ballerini; Eva M Lescano; Miguel A Blanco; Juan J Heinrich; Rodolfo A Rey; Héctor G Jasper Journal: Horm Res Paediatr Date: 2013-12-06 Impact factor: 2.852
Authors: Yun Ning; Alwin G P Schuller; Sheri Bradshaw; Peter Rotwein; Thomas Ludwig; Jan Frystyk; John E Pintar Journal: Mol Endocrinol Date: 2006-05-04
Authors: A C Hokken-Koelega; T Stijnen; M C De Jong; R A Donckerwolcke; S M De Muinck Keizer-Schrama; W F Blum; S L Drop Journal: J Clin Endocrinol Metab Date: 1994-10 Impact factor: 5.958
Authors: Juan P López-Siguero; Maria J Martínez-Aedo; Jose Antonio Bermúdez de la Vega; Jordi Bosch-Muñoz; Alfonso M Lechuga-Sancho; Triana Villalobos Journal: Clin Endocrinol (Oxf) Date: 2021-12-09 Impact factor: 3.523